Literature DB >> 22572497

Dronedarone-current status in management of atrial fibrillation.

Gajendra Manakshe1, B Hygriv Rao.   

Abstract

Atrial fibrillation (AF) is the most common of the serious cardiac rhythm disturbances and is responsible for substantial morbidity and mortality. Available drug therapy for AF has modest efficacy and is associated with the risk of life-threatening pro-arrhythmic complications. Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone and a better side effect profile. It is a multichannel blocker with antiadrenergic properties and has been evaluated in both rate and rhythm control strategies in the management of AF. In this review, we discuss the current role of dronedarone in the contemporary management of AF.
Copyright © 2012 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22572497      PMCID： PMC3860795          DOI： 10.1016/S0019-4832(12)60058-3

Source DB:  PubMed          Journal:  Indian Heart J        ISSN： 0019-4832


  21 in total

1.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  L Samuel Wann; Anne B Curtis; Craig T January; Kenneth A Ellenbogen; James E Lowe; N A Mark Estes; Richard L Page; Michael D Ezekowitz; David J Slotwiner; Warren M Jackman; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Jean-Yves Le Heuzey; Harry J Crijns; James E Lowe; Anne B Curtis; S Bertil Olsson; Kenneth A Ellenbogen; Eric N Prystowsky; Jonathan L Halperin; Juan Luis Tamargo; G Neal Kay; L Samuel Wann; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Judith S Hochman; Christopher E Buller; Frederick G Kushner; Mark A Creager; Erik Magnus Ohman; Steven M Ettinger; William G Stevenson; Robert A Guyton; Lynn G Tarkington; Jonathan L Halperin; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2010-12-21       Impact factor: 24.094

2.  A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.

Authors:  Jean-Yves Le Heuzey; Gaetano M De Ferrari; David Radzik; Massimo Santini; Junren Zhu; Jean-Marc Davy
Journal:  J Cardiovasc Electrophysiol       Date:  2010-04-06

3.  Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.

Authors:  D Roy; M Talajic; P Dorian; S Connolly; M J Eisenberg; M Green; T Kus; J Lambert; M Dubuc; P Gagné; S Nattel; B Thibault
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

4.  Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone.

Authors:  A Varró; J Takács; M Németh; O Hála; L Virág; N Iost; B Baláti; M Agoston; A Vereckei; G Pastor; M Delbruyère; P Gautier; D Nisato; J G Papp
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

5.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Authors:  A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

6.  Increased mortality after dronedarone therapy for severe heart failure.

Authors:  Lars Køber; Christian Torp-Pedersen; John J V McMurray; Ole Gøtzsche; Samuel Lévy; Harry Crijns; Jan Amlie; Jan Carlsen
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

7.  Effect of dronedarone on cardiovascular events in atrial fibrillation.

Authors:  Stefan H Hohnloser; Harry J G M Crijns; Martin van Eickels; Christophe Gaudin; Richard L Page; Christian Torp-Pedersen; Stuart J Connolly
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

8.  Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.

Authors:  Jean-Marc Davy; Martin Herold; Christer Hoglund; Alphons Timmermans; Antonio Alings; David Radzik; Louis Van Kempen
Journal:  Am Heart J       Date:  2008-09       Impact factor: 4.749

9.  Electrophysiologic characterization of dronedarone in guinea pig ventricular cells.

Authors:  Patrick Gautier; Eric Guillemare; Aline Marion; Jean-Philippe Bertrand; Yves Tourneur; Dino Nisato
Journal:  J Cardiovasc Pharmacol       Date:  2003-02       Impact factor: 3.105

10.  Dronedarone in high-risk permanent atrial fibrillation.

Authors:  Stuart J Connolly; A John Camm; Jonathan L Halperin; Campbell Joyner; Marco Alings; John Amerena; Dan Atar; Álvaro Avezum; Per Blomström; Martin Borggrefe; Andrzej Budaj; Shih-Ann Chen; Chi Keong Ching; Patrick Commerford; Antonio Dans; Jean-Marc Davy; Etienne Delacrétaz; Giuseppe Di Pasquale; Rafael Diaz; Paul Dorian; Greg Flaker; Sergey Golitsyn; Antonio Gonzalez-Hermosillo; Christopher B Granger; Hein Heidbüchel; Josef Kautzner; June Soo Kim; Fernando Lanas; Basil S Lewis; Jose L Merino; Carlos Morillo; Jan Murin; Calambur Narasimhan; Ernesto Paolasso; Alexander Parkhomenko; Nicholas S Peters; Kui-Hian Sim; Martin K Stiles; Supachai Tanomsup; Lauri Toivonen; János Tomcsányi; Christian Torp-Pedersen; Hung-Fat Tse; Panos Vardas; Dragos Vinereanu; Denis Xavier; Jun Zhu; Jun-Ren Zhu; Lydie Baret-Cormel; Estelle Weinling; Christoph Staiger; Salim Yusuf; Susan Chrolavicius; Rizwan Afzal; Stefan H Hohnloser
Journal:  N Engl J Med       Date:  2011-11-14       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.